Literature DB >> 301608

Impaired humoral immunity in treated Hodgkin's disease.

S A Weitzman, A C Aisenberg, G R Siber, D H Smith.   

Abstract

To define the contribution of aggressive lymphoma treatment to the risk of post-splenectomy septicemia, we investigated the humoral immunity of 44 patients with Hodgkin's disease. Specific antibody against Haemophilus influenzae Type b was significantly reduced (mean, 147 ng per milliliter, P less than 0.01) in patients receiving combined treatment (radiotherapy and chemotherapy), whereas single treatment reduced titers marginally (chemotherapy) or not at all (radiotherapy). Untreated patients had normal values (396 ng per milliliter), and splenectomy was without effect. In some patients who received combined treatment, titers were reduced to levels seen in infants. IgM levels were likewise normal in untreated patients. Chemotherapy, however, significantly reduced IgM levels (P less than 0.025), an effect potentiated by prior splenectomy. IgG, IgA, alternate-pathway activity, C3, C4 and CH50 were all normal or elevated. Aggressive treatment with chemotherapy and radiation impairs humoral defense against encapsulated micro-organisms, and thus magnifies the risk of post-splenectomy septicemia in patients with Hodgkin's disease.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 301608     DOI: 10.1056/NEJM197708042970504

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  15 in total

1.  Serum IgA to Epstein-Barr virus early antigen-diffuse identifies Hodgkin's lymphoma.

Authors:  Shane C McAllister; Duane Shedd; Nancy E Mueller; Ellen T Chang; George Miller; Sumita Bhaduri-McIntosh
Journal:  J Med Virol       Date:  2013-09-30       Impact factor: 2.327

Review 2.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

3.  The overwhelming postsplenectomy sepsis problem.

Authors:  A S Leonard; G S Giebink; T J Baesl; W Krivit
Journal:  World J Surg       Date:  1980-07       Impact factor: 3.352

4.  [Frequency of hepatitis B virus markers and antibodies to rubella viruses in patients with lymphoproliferative disorders (author's transl)].

Authors:  T Sauerbruch; G Frösner; H Theml; K Eggert; H Kaess
Journal:  Blut       Date:  1980-04

5.  Circulating immune complexes, complement and complement component levels in childhood Hodgkin's disease.

Authors:  W E Brandeis; C Tan; Y Wang; R A Good; N K Day
Journal:  Clin Exp Immunol       Date:  1980-03       Impact factor: 4.330

Review 6.  Long-term complications of laparotomy in Hodgkin's disease.

Authors:  M Jockovich; N P Mendenhall; M D Sombeck; J L Talbert; E M Copeland; K I Bland
Journal:  Ann Surg       Date:  1994-06       Impact factor: 12.969

7.  Iatrogenic and idiopathic acute myelogenous leukemia: a comparison of clinical features and treatment complications.

Authors:  C K Williams; J Cuttner; T Ohnuma; E P Ambinder; P P Ferreira; J F Holland
Journal:  Med Oncol Tumor Pharmacother       Date:  1987

8.  Acute-phase-proteins and parameters of humoral immunity in patients with advanced Hodgkin's disease.

Authors:  C C Zielinski; P Preis; P Aiginger; M M Eibl
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

9.  Development of anti-polysaccharide antibodies in asplenic children.

Authors:  L Hammarström; C I Smith
Journal:  Clin Exp Immunol       Date:  1986-11       Impact factor: 4.330

10.  Spectrum of immunodeficiencies with Hodgkin's disease.

Authors:  J J Twomey; A H Laughter; L Rice; R Ford
Journal:  J Clin Invest       Date:  1980-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.